NDA 210192 · Viiv Hlthcare
Juluca
Dolutegravir Sodium, Rilpivirine Hydrochloride · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Oct 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Nov 21, 2017
Approved uses
3
Original approval plus efficacy supplements
Registered trials
306
91 Phase 3, 30 recruiting
FAERS reports
1,764
926 serious, 98 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 29, 2025.
JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. JULUCA, a two-drug combination of dolutegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. ( 1 )
Mechanism: JULUCA is a fixed-dose combination of the HIV-1 antiretroviral agents, dolutegravir and rilpivirine [see Microbiology ( 12.4 )].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 9, 2021 Supplement 11 · Efficacy LabelLetter
- Jul 14, 2020 Supplement 7 · Efficacy LabelLetter
- Nov 21, 2017 Original approval · Type 4 - New Combination · priority review LabelLetterReview
1 products under this application
- JULUCA · DOLUTEGRAVIR SODIUM EQ 50MG BASE; RILPIVIRINE HYDROCHLORIDE EQ 25MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dolutegravir" as an intervention, any sponsor and status, largest first.
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTPivotal-lookingRecruiting
Africa Health Research InstituteAcademic, hospital or other
NCT06250504 · 2,052 participants (planned) · Start Feb 27, 2024 · Primary completion Apr 30, 2026
Drug: APRETUDE (cabotegravir) 600 mg\3 mL; DAPIRING (Dapivirine) 25mg Vaginal Ring and 2 more · For: HIV Infections
Sites: Somkele, South Africa
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02140255 · 1,120 participants (planned) · Start Jan 23, 2015 · Primary completion Jan 31, 2028
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Nevirapine (NVP) and 5 more · For: HIV Infection
Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 47 sites in all
- ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral TherapyPivotal-lookingCompleted
Professor Francois VenterAcademic, hospital or other
NCT03122262 · 1,110 participants · Start Jan 16, 2017 · Primary completion Apr 30, 2022
Drug: Dolutegravir; Tenofovir Alafenamide and 2 more · For: HIV-1 Infection
Sites: Johannesburg, South Africa · 4 sites in all
- POC HIV Testing and Early DTG Use for InfantsActive, not recruiting
Harvard School of Public Health (HSPH)Academic, hospital or other
NCT05393193 · 900 participants (planned) · Start Jul 4, 2022 · Primary completion Mar 16, 2026
Drug: DTG/ABC/3TC · For: HIV
Sites: Gaborone, Botswana
- Antiretroviral Therapy for Acute and Chronic HIV InfectionPivotal-lookingRecruiting
SEARCH Research FoundationAcademic, hospital or other
NCT00796263 · 900 participants (planned) · Start May 13, 2009 · Primary completion Jun 2033
Drug: HAART · For: Acute HIV Infection; Chronic HIV Infection
Sites: Bangkok, Thailand
- Optimizing Malaria Treatment for HIV-Malaria Co-infected IndividualsPivotal-lookingStatus unknown
Makerere UniversityAcademic, hospital or other
NCT04708496 · 888 participants (planned) · Start Jan 18, 2021 · Primary completion Jan 2024
Drug: Artemether-lumefantrine · For: HIV Coinfection; Malaria
Sites: Kampala, Uganda; Tororo, Uganda
- Shortened Regimen for Drug-susceptible TB in ChildrenPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06253715 · 860 participants (planned) · Start Jan 15, 2025 · Primary completion Sep 30, 2027
Drug: Isoniazid; Rifampin and 4 more · For: Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node and 1 more
Sites: Chennai, India; Pune, India; Bandung, Indonesia · 9 sites in all
- A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)Pivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT01263015 · 844 participants · Start Feb 1, 2011 · Primary completion May 14, 2012
Drug: Dolutegravir; Atripla and 4 more · For: Infection, Human Immunodeficiency Virus I
Sites: Hobson City, Alabama; Little Rock, Arkansas; Bakersfield, California · 145 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain312
- product dose omission issue296
- anxiety285
- emotional distress278
- anhedonia251
- chronic kidney disease204
- renal failure132
- fatigue125
- depression120
- osteoporosis92
- acute kidney injury88
- economic problem84
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 153 |
| 2019 | 263 |
| 2020 | 218 |
| 2021 | 171 |
| 2022 | 240 |
| 2023 | 247 |
| 2024 | 218 |
| 2025 | 189 |
| 2026 | 60 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Juluca (Dolutegravir/Rilpivirine)
2024 spending
$415M
Beneficiaries
12,112
112,878 claims
Per beneficiary
$34,282
$116.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $252,273,517 |
| 2021 | $298,134,488 |
| 2022 | $346,740,919 |
| 2023 | $392,257,065 |
| 2024 | $415,220,185 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Equivalence Trial
- Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.
Figueroa MI, Brites C, Cecchini D, et al. · Clin Infect Dis 2026 · Randomized Controlled Trial, Multicenter Study
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, et al. · Lancet HIV 2025 · Multicenter Study, Randomized Controlled Trial
- Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
Cahn P, Sierra Madero J, Arribas JR, et al. · AIDS 2022 · Clinical Trial, Phase III, Multicenter Study
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, et al. · Lancet 2017 · Clinical Trial, Phase III, Comparative Study
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, et al. · Lancet HIV 2020 · Clinical Trial, Phase III, Comparative Study
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.